Mapping the global use of different BCG vaccine strains

Tuberculosis

Volumn 89, Issue 4, 2009, Pages 248-251

  Ritz, Nicole ^a,b   Curtis, Nigel ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

BCG; Immunisation; Map; Strain; Vaccine

Indexed keywords

BCG VACCINE;

ARTICLE; BACTERIAL STRAIN; BCG VACCINATION; DRUG EFFICACY; DRUG PREFERENCE; DRUG SURVEILLANCE PROGRAM; GENETIC STRAIN; INCIDENCE; NONHUMAN; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; STRAIN DIFFERENCE; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; HUMANS; MYCOBACTERIUM BOVIS; SPECIES SPECIFICITY; TUBERCULOSIS; VACCINATION; WORLD HEALTH;

EID: 67650617696     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2009.03.002     Document Type: Article

References (26)

1. Weill-Hallé B., and Turpin R. Premières essay de vaccination antituberculeuse de l'enfent par le bacille Calmette-Guérin. Bulletin et Mémoires de la Société Médicale des Hôpitaux de Paris 49 (1925) 1589-1601
2. Petroff S.A., and Branch A. Bacillus Calmette-Guérin (B.C.G.). Animal experimentation and prophylactic immunization of children. Am J Public Health 18 7 (1928 July) 843-864
3. Milstien J.B., and Gibson J.J. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 68 1 (1990) 93-108
4. Mahairas G.G., Sabo P.J., Hickey M.J., Singh D.C., and Stover C.K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 178 5 (1996 Mar) 1274-1282
5. Collins D.M., and De Lisle G.W. BCG identification by DNA restriction fragment patterns. J Gen Microbiol 133 6 (1987 Jun) 1431-1434
6. Fomukong N.G., Dale J.W., Osborn T.W., and Grange J.M. Use of gene probes based on the insertion sequence IS986 to differentiate between BCG vaccine strains. J Appl Bacteriol 72 2 (1992 Feb) 126-133
7. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik K., Rane S., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284 5419 (1999 May 28) 1520-1523
8. Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A 104 13 (2007 Mar 27) 5596-5601
9. Mostowy S., Tsolaki A.G., Small P.M., and Behr M.A. The in vitro evolution of BCG vaccines. Vaccine 21 27-30 (2003 Oct 1) 4270-4274
10. Behr M.A. BCG-different strains, different vaccines?. Lancet Infect Dis 2 2 (2002 Feb) 86-92
11. Behr M.A. Comparative genomics of BCG vaccines. Tuberculosis (Edinb) 81 1-2 (2001) 165-168
12. Behr M.A., Schroeder B.G., Brinkman J.N., Slayden R.A., and Barry III C.E. A point mutation in the mma3 gene is responsible for impaired methoxymycolic acid production in Mycobacterium bovis BCG strains obtained after 1927. J Bacteriol 182 12 (2000 Jun) 3394-3399
13. Behr M.A., and Small P.M. A historical and molecular phylogeny of BCG strains. Vaccine 17 7-8 (1999 Feb 26) 915-922
14. Ritz N., Hanekom W.A., Robins-Browne R., Britton W.J., and Curtis N. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev 32 5 (2008 Aug) 821-841
15. Behr M.A. Correlation between BCG genomics and protective efficacy. Scand J Infect Dis 33 4 (2001) 249-252
16. Kroger L., Korppi M., Brander E., Kroger H., Wasz-Hockert O., Backman A., et al. Osteitis caused by bacille Calmette-Guerin vaccination: a retrospective analysis of 222 cases. J Infect Dis 172 2 (1995 Aug) 574-576
17. Marik I., Kubat R., Filipsky J., and Galliova J. Osteitis caused by BCG vaccination. J Pediatr Orthop 8 3 (1988 May-Jun) 333-337
18. Ritz N., Tebruegge M., Connell T.G., Sievers A., Robins-Browne R., and Curtis N. Susceptibility of BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother 53 1 (2009) 316-318
19. Davids V., Hanekom W.A., Mansoor N., Gamielden H., Gelderbloem S.J., Hawkridge A., et al. The effect of bacille Calmette-Guerin vaccine strain and route of administration on induced immune responses in vaccinated infants. J Infect Dis 193 4 (2006 Feb 15) 531-536
20. Hawkridge A., Hatherill M., Little F., Goetz M.A., Barker L., Mahomed H., et al. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 337 (2008) a2052
21. Zwerling A, Behr M, Brewer T, Menzies D, Pai M. BCG World Atlas. Available from: http://www.bcgatlas.org/index.php [cited 2008 18 Dec].
22. Infuso A., and Falzon D. European survey of BCG vaccination policies and surveillance in children, 2005. Euro Surveill 11 3 (2006 Mar) 6-11
23. World Health Organization. Bacille Calmette Guérin vaccine: Reported estimates of BCG coverage. Available from: (2008). http://www.who.int/vaccines/globalsummary/immunization/timeseries/tscoveragebcg.htm [cited 2008 19 Dec]
24. Australian New Zealand Clinical Trials Registry. Bacille Calmette-Guérin (BCG) immune response study. Available from: (2008). http://www.anzctr.org.au/trial_view.aspx?ACTRN=12608000227392 [cited 2009 12 Jan]
25. Corbel M.J., Fruth U., Griffiths E., and Knezevic I. Report on a WHO consultation on the characterisation of BCG strains, Imperial College, London 15-16 December 2003. Vaccine 22 21-22 (2004 Jul 29) 2675-2680
26. World Health Organization. Global TB database. Available from: (2008). http://www.who.int/tb/country/global_tb_database/en/ [cited Dec 18, 2008]